Evidence map›Paper›PMID 38370423›Full record

ArticleJournal of medical imaging (Bellingham, Wash.)2024

End-to-end deep learning method for predicting hormonal treatment response in women with atypical endometrial hyperplasia or endometrial cancer.

Seyed Kahaki, Ian S Hagemann, Kenny H Cha, Christopher Trindade, Nicholas Petrick, Nicolas Kostelecky, Lindsay E Borden, Doaa Atwi, Kar-Ming Fung, Weijie Chen

Abstract read
In one paragraph

Article in Journal of medical imaging (Bellingham, Wash.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Seyed KahakiU.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health, Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Silver Spring, Maryland, United States.ORCID https://orcid.org/0000-0002-0249-3238
Ian S HagemannWashington University School of Medicine, Department of Pathology and Immunology, St. Louis, Missouri, United States.ORCID https://orcid.org/0000-0002-3855-9745
Kenny H ChaU.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health, Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Silver Spring, Maryland, United States.ORCID https://orcid.org/0000-0003-3847-7448
Christopher TrindadeU.S. Food and Drug Administration (FDA), Division of Molecular Genetics and Pathology, Silver Spring, Maryland, United States.
Nicholas PetrickU.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health, Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Silver Spring, Maryland, United States.ORCID https://orcid.org/0000-0001-5167-8899
Nicolas KosteleckyWashington University School of Medicine, Department of Pathology and Immunology, St. Louis, Missouri, United States.
Lindsay E BordenUniversity of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Oklahoma City, Oklahoma, United States.
Doaa AtwiUniversity of Oklahoma Health Sciences Center, Department of Pathology, Oklahoma City, Oklahoma, United States.
Kar-Ming FungUniversity of Oklahoma Health Sciences Center, Department of Pathology, Oklahoma City, Oklahoma, United States.
Weijie ChenU.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health, Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Silver Spring, Maryland, United States.

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Route 66 Endometrial Cancer SPOREP50CA265793 · NCI · WASHINGTON UNIVERSITY · PI Esther Jiaxin Lu · 2023 to 2026
$11.6M
NCI NIH HHS P30 CA225520NCI NIH HHS P50 CA265793
6 · The paper itself

Abstract

Purpose: Endometrial cancer (EC) is the most common gynecologic malignancy in the United States, and atypical endometrial hyperplasia (AEH) is considered a high-risk precursor to EC. Hormone therapies and hysterectomy are practical treatment options for AEH and early-stage EC. Some patients prefer hormone therapies for reasons such as fertility preservation or being poor surgical candidates. However, accurate prediction of an individual patient's response to hormonal treatment would allow for personalized and potentially improved recommendations for these conditions. This study aims to explore the feasibility of using deep learning models on whole slide images (WSI) of endometrial tissue samples to predict the patient's response to hormonal treatment. Approach: We curated a clinical WSI dataset of 112 patients from two clinical sites. An expert pathologist annotated these images by outlining AEH/EC regions. We developed an end-to-end machine learning model with mixed supervision. The model is based on image patches extracted from pathologist-annotated AEH/EC regions. Either an unsupervised deep learning architecture (Autoencoder or ResNet50), or non-deep learning (radiomics feature extraction) is used to embed the images into a low-dimensional space, followed by fully connected layers for binary prediction, which was trained with binary responder/non-responder labels established by pathologists. We used stratified sampling to partition the dataset into a development set and a test set for internal validation of the performance of our models. Results: The autoencoder model yielded an AUROC of 0.80 with 95% CI [0.63, 0.95] on the independent test set for the task of predicting a patient with AEH/EC as a responder vs non-responder to hormonal treatment. Conclusions: These findings demonstrate the potential of using mixed supervised machine learning models on WSIs for predicting the response to hormonal treatment in AEH/EC patients.

Indexed as

atypical endometrial hyperplasiadeep learninghormonal treatmentmixed supervised learning

Identifiers

PMID38370423
PMCPMC10868592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.